DOJ Sues KV Pharmaceutical Over Adulterated Drug Production

The U.S. Department of Justice (DOJ) has filed a lawsuit to block KV Pharmaceutical (St. Louis), its subsidiaries Ethex and Ther-Rx, as well as its principal officers from manufacturing and distributing adulterated and unapproved drugs. KV has agreed to the injunction in a consent decree, DOJ says. KV Pharmaceutical is a specialty drugmaker that develops, manufactures, and markets branded and generic prescription products and had revenues of about $600 million in fiscal 2008. FDA says it conducted inspections of the company’s facilities between December...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers